Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

OncoResponse

5 Disclosed Funding Rounds $103,100,000

0 Participating Investments


Biopharma, Therapeutics, Health Care, Biotechnology

OncoResponse is a company providing cancer research into immunotherapies and the newest technologies for oncologists.

Seattle, Washington, United States, North America (US)

Organizations in Seattle in Biopharma,
Organizations in Seattle in Therapeutics,
Organizations in Seattle in Health Care,
Organizations in Seattle in Biotechnology,
Organizations in Washington in Biopharma,
Organizations in Washington in Therapeutics,
Organizations in Washington in Health Care,
Organizations in Washington in Biotechnology,
Organizations in United States in Biopharma,
Organizations in United States in Therapeutics,
Organizations in United States in Health Care,
Organizations in United States in Biotechnology,
Organizations in North America in Biopharma,
Organizations in North America in Therapeutics,
Organizations in North America in Health Care,
Organizations in North America in Biotechnology

Investors in Seattle in Biopharma,
Investors in Seattle in Therapeutics,
Investors in Seattle in Health Care,
Investors in Seattle in Biotechnology,
Investors in Washington in Biopharma,
Investors in Washington in Therapeutics,
Investors in Washington in Health Care,
Investors in Washington in Biotechnology,
Investors in United States in Biopharma,
Investors in United States in Therapeutics,
Investors in United States in Health Care,
Investors in United States in Biotechnology,
Investors in North America in Biopharma,
Investors in North America in Therapeutics,
Investors in North America in Health Care,
Investors in North America in Biotechnology

West Coast (0 Investors) (0 Startups), Greater Seattle Area (0 Investors) (0 Startups), Western US (0 Investors) (0 Startups)

Founded date 01, 2015

Founders Clifford J. Stocks

Operating Status Active

Funding Stage Late Stage Venture

Last Funding Type Series C

Company Type For Profit


Wikipedia Link

OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, to interrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.

Date Round Raised Lead
March, 31, 2021 Series C $40,600,000 Magnetar Capital
September, 11, 2018 Series B $40,000,000 RiverVest
March, 09, 2017 Series A $3,000,000 -------
October, 10, 2016 Series A $7,000,000 Helsinn Investment Fund, GreatPoint Ventures
May, 07, 2016 Series A $12,500,000 Baxalta, ARCH Venture Partners

OncoResponse Investors (26)

Investor Lead? Round Participating Raise Date Partners
Bering Capital No Series C $40,600,000 March, 31, 2021 -------
Yonjin Venture No Series C $40,600,000 March, 31, 2021 -------
RiverVest No Series C $40,600,000 March, 31, 2021 -------
Redmile Group No Series C $40,600,000 March, 31, 2021 -------
Qatar Investment Authority No Series C $40,600,000 March, 31, 2021 -------
Magnetar Capital Yes Series C $40,600,000 March, 31, 2021 -------
Helsinn Investment Fund No Series C $40,600,000 March, 31, 2021 -------
Canaan Partners No Series C $40,600,000 March, 31, 2021 -------
ARCH Venture Partners No Series C $40,600,000 March, 31, 2021 -------
RiverVest Yes Series B $40,000,000 September, 11, 2018 -------
Canaan Partners No Series B $40,000,000 September, 11, 2018 -------
Redmile Group No Series B $40,000,000 September, 11, 2018 -------
Qatar Investment Authority No Series B $40,000,000 September, 11, 2018 -------
HT Family Office No Series B $40,000,000 September, 11, 2018 -------
ARCH Venture Partners No Series B $40,000,000 September, 11, 2018 -------
Alexandria Venture Investments No Series B $40,000,000 September, 11, 2018 -------
Rice University No Series B $40,000,000 September, 11, 2018 -------
Helsinn Investment Fund No Series B $40,000,000 September, 11, 2018 -------
Helsinn Investment Fund Yes Series A $7,000,000 October, 10, 2016 -------
GreatPoint Ventures Yes Series A $7,000,000 October, 10, 2016 -------
Alexandria Real Estate Equities No Series A $12,500,000 May, 07, 2016 -------
Rice University No Series A $12,500,000 May, 07, 2016 -------
Canaan Partners No Series A $12,500,000 May, 07, 2016 -------
Baxalta Yes Series A $12,500,000 May, 07, 2016 -------
The University of Texas M.D. Anderson Cancer Center No Series A $12,500,000 May, 07, 2016 -------
ARCH Venture Partners Yes Series A $12,500,000 May, 07, 2016 -------